Accéder au contenu
Merck

EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer.

Biomolecules (2021-05-01)
Song-Hee Kim, Byung-Chul Kang, Daseul Seong, Won-Hyeok Lee, Jae-Hee An, Hyoung-Uk Je, Hee-Jeong Cha, Hyo-Won Chang, Sang-Yoon Kim, Seong-Who Kim, Myung-Woul Han
RÉSUMÉ

EPHA3, a member of the EPH family, is overexpressed in various cancers. We demonstrated previously that EPHA3 is associated with radiation resistance in head and neck cancer via the PTEN/Akt/EMT pathway; the inhibition of EPHA3 significantly enhances the efficacy of radiotherapy in vitro and in vivo. In this study, we investigated the mechanisms of PTEN regulation through EPHA3-related signaling. Increased DNA methyltransferase 1 (DNMT1) and enhancer of zeste homolog 2 (EZH2) levels, along with increased histone H3 lysine 27 trimethylation (H3K27me3) levels, correlated with decreased levels of PTEN in radioresistant head and neck cancer cells. Furthermore, PTEN is regulated in two ways: DNMT1-mediated DNA methylation, and EZH2-mediated histone methylation through EPHA3/C-myc signaling. Our results suggest that EPHA3 could display a novel regulatory mechanism for the epigenetic regulation of PTEN in radioresistant head and neck cancer cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
3-Deazaneplanocin A hydrochloride, ≥97% (HPLC)